Showing results (141-150 of 190) with videos related to
Sort By:
Pageof 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 13, 2024
Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic MalignanciesJason J Luke, Karen Gelmon, Lillian L Siu, et al.Medrxiv : the Preprint Server for Health Sciences|May 7, 2024
Radiomic analysis of patient and inter-organ heterogeneity in response to immunotherapies and BRAF targeted therapy in metastatic melanomaAlexandra Tompkins, Zane N Gray, Rebekah E Dadey, et al.Nature Medicine|October 13, 2022
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trialRichard D Carvajal, Marcus O Butler, Alexander N Shoushtari, et al.Journal of Translational Medicine|July 23, 2018
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy)Paolo A Ascierto, Igor Puzanov, Sanjiv S Agarwala, et al.Journal for Immunotherapy of Cancer|February 20, 2021
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumorsJason J Luke, Fabrice Barlesi, Ki Chung, et al.Cancer|August 6, 2013
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experienceJason J Luke, Margaret K Callahan, Michael A Postow, et al.Cancer|August 18, 2016
The efficacy of anti-PD-1 agents in acral and mucosal melanomaAlexander N Shoushtari, Rodrigo R Munhoz, Deborah Kuk, et al.Frontiers in Immunology|July 12, 2023
Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomesLilit Karapetyan, Hassan M AbuShukair, Aofei Li, et al.The Oncologist|May 30, 2013
Ipilimumab for patients with advanced mucosal melanomaMichael A Postow, Jason J Luke, Mark J Bluth, et al.Therapeutic Advances in Medical Oncology|April 22, 2020
Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancerDavid W Doo, Selene Meza-Perez, Angelina I Londoño, et al.Pageof 19